Anteris Technologies Global (NASDAQ:AVR) and CollPlant Biotechnologies (NASDAQ:CLGN) Financial Comparison

Anteris Technologies Global (NASDAQ:AVR) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Anteris Technologies Global and CollPlant Biotechnologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	0	0	4	0	3.00
CollPlant Biotechnologies	0	0	2	1	3.33

Anteris Technologies Global presently has a consensus price target of $16.50, indicating a potential upside of 165.70%. CollPlant Biotechnologies has a consensus price target of $12.50, indicating a potential upside of 300.00%. Given CollPlant Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Anteris Technologies Global.

Valuation and Earnings

This table compares Anteris Technologies Global and CollPlant Biotechnologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$2.71 million	82.52	N/A	N/A	N/A
CollPlant Biotechnologies	$650,000.00	55.07	-$7.02 million	($1.54)	-2.03

Anteris Technologies Global has higher revenue and earnings than CollPlant Biotechnologies.

Insider & Institutional Ownership

21.7% of CollPlant Biotechnologies shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Anteris Technologies Global and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	N/A	N/A	N/A
CollPlant Biotechnologies	-2,680.00%	-77.05%	-61.43%

Summary

Anteris Technologies Global beats CollPlant Biotechnologies on 6 of the 11 factors compared between the two stocks.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.